...Technology and Quality Officer Heow Tan, who held the same position at Pharmacyclics.Pharmacyclics developed Imbruvica ibrutinib...

...inhibitors on the market such as Imbruvica ibrutinib...
...will test the covalent inhibitor head-to-head against Imbruvica.Without...

...non-inferior progression-free survival in adults with previously treated, high-risk chronic lymphocytic leukemia compared to Imbruvica ibrutinib...
...A4250) Sulopenem etzadroxil-probenecid (PF-03709270) Calquence (Brand), ACP-196 (Compound #), acalabrutinib (Generic) Imbruvica (Brand), PCI-32765 (Compound #), ibrutinib (Generic), Imbruvica...

...LOTIS 3 study evaluating Lonca with Ibrance ibrutinib...

...inhibitor Imbruvica ibrutinib, but it also raises the question of how it stacks up to Imbruvica...
...a Phase III study against Imbruvica in treatment-naïve CLL/SLL scheduled to begin later in the year.Imbruvica...
...tyrosine kinaseRET – Ret proto-oncogene Lauren Martz LY3527727 (LOXO-305, REDX08608, rxc005) Imbruvica (Brand), PCI-32765 (Compound #), ibrutinib (Generic), Imbruvica...

...NYSE:ABBV) for documents regarding pricing strategies for autoimmune drug Humira adalimumab and cancer therapy Imbruvica ibrutinib...

...the Btk inhibitor to compete with Imbruvica ibrutinib...
...lymphoma (SLL) and mantle cell lymphoma (MCL). Imbruvica...

...program off the ground. Sales from AbbVie’s two marketed cancer drugs, Venclexta venetoclax and Imbruvica ibrutinib...

...royalty transactions since 1996, including deals for 45 marketed therapies. Among them are blockbusters Imbruvica ibrutinib...

...targets CD19. In a separate Phase I/II trial evaluating loncastuximab tesirine plus Btk inhibitor Imbruvica ibrutinib...